Paediatric Cancer Treatment in India: Complete Guide for International Families
Priya Sharma
Oncology & Cancer Care Writer
TL;DR: Childhood cancer treatment in India costs USD 10,000–45,000 for a complete course — 65–75% less than the USA. ALL (leukaemia) remission rate: 85–90%. Bone marrow transplant for thalassaemia: 80–90% cure rate at USD 25,000–40,000. Tata Memorial Mumbai and Apollo Delhi treat 2,000+ new paediatric cancer cases annually.
A cancer diagnosis in a child is devastating under any circumstances. Receiving that diagnosis in a country where treatment costs USD 100,000 or more — or where the treatment simply isn't available — adds a layer of helplessness that no family should face.
India changes that equation. This guide explains how paediatric cancer care in India works, what it costs, which centres lead in different cancer types, and how to plan the journey.
Why India for Childhood Cancer Treatment?
Treatment Quality
India's leading paediatric oncology centres follow the same treatment protocols as Western institutions — Children's Oncology Group (COG) protocols for leukaemia, SIOP protocols for solid tumours, and standard BMT conditioning regimens. The drugs are the same. The chemotherapy agents are the same. The difference is price.
Cost comparison for paediatric cancer treatment:
| Treatment | India | USA | UK |
|---|---|---|---|
| ALL chemotherapy (full 2-year course) | USD 12,000–20,000 | USD 100,000–300,000 | £50,000–150,000 |
| AML chemotherapy | USD 15,000–25,000 | USD 150,000–400,000 | £80,000–200,000 |
| Wilms tumour (nephrectomy + chemo) | USD 8,000–15,000 | USD 50,000–120,000 | £25,000–60,000 |
| Neuroblastoma (surgery + chemo + MIBG) | USD 15,000–35,000 | USD 200,000–500,000 | £100,000–300,000 |
| Brain tumour (surgery + radiation) | USD 10,000–20,000 | USD 80,000–200,000 | £40,000–120,000 |
| Autologous BMT | USD 20,000–35,000 | USD 150,000–300,000 | £80,000–200,000 |
| Allogeneic BMT (sibling donor) | USD 30,000–50,000 | USD 200,000–400,000 | £100,000–250,000 |
Outcome Data
At India's top paediatric oncology centres:
- ALL (acute lymphoblastic leukaemia): Complete remission rate 85–90%; 5-year event-free survival 75–80%
- AML: Complete remission 70–80%; 5-year survival 40–55% with BMT
- Wilms tumour: Overall survival 80–85% with current protocols
- Hodgkin lymphoma: 5-year progression-free survival 85–90%
- Thalassaemia (cured by BMT): 80–90% disease-free survival with matched sibling donor
These figures are published in peer-reviewed journals and are comparable to outcomes at UK and US paediatric oncology centres.
Paediatric Cancers Treated in India
Blood Cancers (Leukaemias and Lymphomas)
Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer — accounting for 25–30% of all paediatric cancers. India has exceptional experience treating ALL with COG/BFM protocols including induction, consolidation, and maintenance phases totalling 2–2.5 years.
Acute myeloid leukaemia (AML) is treated with intensive chemotherapy followed by BMT in high-risk cases.
Hodgkin lymphoma: India's outcomes match those of Western centres using ABVD or BEACOPP protocols. Radiation therapy is available where indicated.
Non-Hodgkin lymphoma: Burkitt lymphoma, DLBCL, and anaplastic large cell lymphoma (ALCL) are treated with protocol-driven chemotherapy.
Solid Tumours
Wilms tumour (nephroblastoma): Kidney cancer in children. Surgery (nephrectomy or partial nephrectomy) + chemotherapy, sometimes radiation. India's urological oncology teams have extensive experience.
Neuroblastoma: Adrenal or abdominal tumour in young children. Treatment depends on risk group — low risk (surgery only) through high risk (surgery + intensive chemo + autologous BMT + MIBG therapy + isotretinoin).
Retinoblastoma: Eye cancer in infants and young children. India is a global centre for intra-arterial chemotherapy (IAC) for retinoblastoma — avoiding eye removal in many cases. LV Prasad Eye Institute and Sankara Nethralaya lead in this area.
Osteosarcoma and Ewing sarcoma: Bone cancers in teenagers. Multi-agent chemotherapy + surgery (limb salvage or amputation) + post-operative chemotherapy. India's orthopaedic oncologists perform limb salvage in 85–90% of eligible cases.
Rhabdomyosarcoma: Soft tissue sarcoma in children. Multimodal treatment with chemotherapy, surgery, and radiation.
Brain tumours: Medulloblastoma (most common paediatric brain tumour), pilocytic astrocytoma, ependymoma, and DIPG. Neurosurgery + radiation + chemotherapy. India's neurosurgeons have specific training in paediatric brain tumour resection with intraoperative monitoring.
Bone Marrow Transplant (BMT) for Blood Disorders
Beyond cancer, BMT is the only cure for several serious blood conditions in children:
Thalassaemia major: Children with thalassaemia major require lifelong blood transfusions unless cured by BMT. With a matched sibling donor, India's BMT centres achieve 80–90% cure rates. India performs more thalassaemia BMTs annually than any other country — the experience and volume translate to expertise.
Sickle cell disease: BMT from a matched sibling cures sickle cell disease. Cost: USD 25,000–40,000 in India. Particularly relevant for families from Nigeria, Ghana, and other West African countries where sickle cell is prevalent.
Aplastic anaemia: Severe aplastic anaemia in children is treated by immunosuppression first; if this fails, allogeneic BMT from a sibling or unrelated donor is curative in 80–90% of cases.
SCID (Severe Combined Immunodeficiency): Bone marrow transplant is curative and must be done early in infancy. India's BMT centres have treated children as young as 6 months.
Leading Hospitals for Paediatric Cancer Treatment
Tata Memorial Hospital, Mumbai
India's premier cancer centre, operated by the Government of India's Department of Atomic Energy. Tata Memorial treats over 70,000 new cancer patients annually, including 2,000+ new paediatric cancer cases. It has a dedicated paediatric oncology ward with 100+ beds, a bone marrow transplant unit, and a paediatric surgical oncology team.
Strengths: Highest volume in India, government institution (lower cost), all cancer types covered, leading BMT programme.
International patients: Tata Memorial accepts international patients through a formal referral process. Arodya can arrange direct consultation letters.
Apollo Cancer Centres, Delhi and Chennai
JCI-accredited. Apollo's paediatric oncology programme has dedicated paediatric haematologists, oncologists, and a BMT unit. The international patient infrastructure is comprehensive — dedicated coordinators, accommodation assistance, and English-language medical records.
Strengths: JCI accreditation, international patient focus, strong paediatric BMT programme.
CMC (Christian Medical College), Vellore
Consistently ranked among India's top 3 hospitals. CMC Vellore has one of India's oldest and most respected haematology and BMT programmes. Particularly strong in thalassaemia and sickle cell BMT.
Strengths: Thalassaemia and haemoglobinopathy BMT, outstanding nursing care, lower cost than Delhi or Mumbai private hospitals.
AIIMS Delhi
Premier public academic institution. AIIMS Delhi's paediatric oncology department handles complex cases and trains India's oncologists. Lower cost than private hospitals; longer waiting times for elective cases.
Rajiv Gandhi Cancer Institute (RGCI), Delhi
Dedicated cancer hospital in Delhi. Strong paediatric oncology unit with a BMT programme. Good choice for families based in North India.
The Treatment Journey: What Families Should Expect
Before Travel: Records and Pre-Assessment
Send all records before booking flights:
- Biopsy reports / pathology slides (ideally physical slides that can be re-reviewed)
- Imaging: CT scan, MRI, PET-CT (CD format)
- Blood reports (full blood count, LFT, RFT, coagulation)
- Bone marrow biopsy report (if performed)
- Any treatment already received (chemotherapy cycle details)
The paediatric oncology team will review records within 3–5 days and provide a written treatment plan and cost estimate.
Phase 1: Diagnosis and Staging (Week 1–2 in India)
On arrival:
- Confirm or repeat key diagnostic tests (the team may request a repeat bone marrow biopsy or fresh MRI if records are incomplete)
- Multi-disciplinary tumour board review — the case is discussed by oncologists, surgeons, radiologists, and radiotherapists together
- Initiation of treatment (in leukaemia, chemotherapy often starts within 48–72 hours of confirmed diagnosis)
Phase 2: Initial Treatment (Weeks 2–8)
For leukaemia: First 4 weeks of induction chemotherapy in hospital, followed by consolidation as an outpatient or brief inpatient admissions.
For solid tumours: Surgery (if indicated upfront) + initial chemotherapy cycles.
For BMT candidates: HLA typing of patient and potential donors; donor selection; pre-BMT chemotherapy conditioning; transplant.
Important for long-term treatment: ALL maintenance chemotherapy lasts 2–2.5 years total. International families typically complete induction (first 4–8 weeks) in India, then return to their home country with the chemotherapy protocol in writing for a local oncologist to administer. Arodya connects families with paediatric oncologists in African countries for continuation of care.
Phase 3: Follow-Up and Monitoring
India's oncology teams provide:
- Complete written discharge summaries
- Chemotherapy protocol in standard format (sharable with home oncologists)
- Contact for telemedicine follow-up
- Referral to paediatric oncologists in Africa where available
Families return to India for scheduled bone marrow assessments, end-of-treatment evaluations, and any treatment intensification decisions.
Practical Information
Visa
Patient: Medical Visa (M-Visa). Both parents: Medical Attendant Visa (MX-Visa). Apply with hospital appointment letter and medical records. Processing: 3–7 days; urgent cases 24–48 hours.
Accommodation
Most families rent serviced apartments near the hospital for extended stays (1–3 months for induction chemotherapy + BMT). Cost: USD 25–60/night. Some hospitals have on-campus family accommodation. Arodya arranges this on request.
Cost Planning
For long-term treatment (leukaemia, BMT), costs are not a single upfront payment — they are distributed across:
- Induction phase (weeks 1–8): highest cost, most intensive
- Consolidation and maintenance: lower per-cycle costs, many cycles administered at home
- BMT (if required): single high-cost event
Arodya provides a phased cost breakdown and payment schedule from the hospital before treatment begins.
How Arodya Helps
Arodya coordinates every step at no cost to the family:
- Diagnosis review: Arrange specialist second opinion before travel
- Hospital matching: Match diagnosis and budget to the right centre
- Treatment estimate: Written cost estimate from hospital before travel
- Visa support: Hospital appointment letters for visa application
- On-arrival coordination: Airport, hotel, hospital registration
- During treatment: Daily coordinator, translation, medication sourcing
- Home continuation: Connect with paediatric oncologists in your home country
- Return visits: Coordinate follow-up admissions
Submit your child's case through the form on this page to get started.
